EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Cancer Cell · 2025-03 · 43 (3) · 537-551.e7
DOI: 10.1016/j.ccell.2025.01.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025-03. Verfasst von Patrizia Porazzi und 29 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University o…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Immunotherapy, Adoptive, Polycomb Repressive Complex 2, Pyridones. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Stichting Lymph&Co, Parker Institute for Cancer Immunotherapy.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Lymphoma Program, Abramson Canc…
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; School of Medicine, Università…
- Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
- Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Förderung
- NCI NIH HHS
- Stichting Lymph&Co
- Parker Institute for Cancer Immunotherapy
- Laffey-McHugh Foundation
- National Cancer Institute
Zitieren
APA
Porazzi, P., Nason, S., Yang, Z., Carturan, A., Ghilardi, G., Guruprasad, P., Patel, R. P., Tan, M., Padmanabhan, A. A., Lemoine, J., Fardella, E., Zhang, Y., Pajarillo, R., Chen, L., Ugwuanyi, O., Markowitz, K., Delman, D., Angelos, M. G., Shestova, O., …, & Ruella, M. (2025). EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell, 43(3), 537-551.e7. https://doi.org/10.1016/j.ccell.2025.01.013
Vancouver
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537-551.e7. doi:10.1016/j.ccell.2025.01.013
BibTeX
@article{Porazzi2025,
author = {Porazzi, Patrizia and Nason, Siena and Yang, Ziqi and Carturan, Alberto and Ghilardi, Guido and Guruprasad, Puneeth and Patel, Ruchi P and Tan, Melody and Padmanabhan, Anushka Anant and Lemoine, Jean and Fardella, Eugenio and Zhang, Yunlin and Pajarillo, Raymone and Chen, Linhui and Ugwuanyi, Ositadimma and Markowitz, Kelly and Delman, Devora and Angelos, Mathew G and Shestova, Olga and Isshiki, Yusuke and Blanchard, Tatiana and Béguelin, Wendy and Melnick, Ari M and Linette, Gerald P and Beatty, Gregory L and Carreno, Beatriz M and Cohen, Ivan J and Paruzzo, Luca and Schuster, Stephen J and Ruella, Marco},
title = {EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {3},
pages = {537--551.e7},
doi = {10.1016/j.ccell.2025.01.013}
}
EUVIMED